News on science and technology in Guinea-Bissau
Provided by AGP
MENAFN
(MENAFN) Guinea-Bissau has terminated a contentious hepatitis B vaccine trial bankrolled by the Trump administration following a sharp ethical rebuke from the World Health Organization (WHO), which warned the study risked causing irreversible harm...
MENAFN
(MENAFN) Guinea-Bissau has terminated a controversial hepatitis B vaccine study financed by the administration of US President Donald Trump after the World Health Organization raised ethical concerns about the project’s design.
GlobeNewswire, Inc.
HOUSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (the “Company” or “Itafos”) today reported its Q1 2026 financial results and provided a corporate update.
EIN Presswire
On-the-ground investigation raised alarms about safeguards for children, conflicts of interest, and grant oversight.
EIN Presswire
Following WHO’s statement of concern, Stand Up For Science urges immediate action to halt unethical research practices.
GlobeNewswire, Inc.
HOUSTON, April 17, 2026 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (“Itafos” or “the Company”) today announces that its financial results for Q1 2026 will be released after market close on Wednesday, April 29, 2026. An on-demand...
The daily local news briefing you can trust. Every day. Subscribe now.
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
is already signed up. Check your inbox for updates.